This is a preview of subscription content, log in via an institution to check access.
Notes
incremental cost-effectiveness ratios
Reference
Bentley A, et al. Cost-Utility Analysis of Deferiprone for the Treatment of beta-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective. PharmacoEconomics : 20 Jul 2013. Available from: URL: http://dx.doi.org/10.1007/s40273-013-0076-z
Rights and permissions
About this article
Cite this article
Deferiprone shows its metal. PharmacoEcon Outcomes News 684, 5 (2013). https://doi.org/10.1007/s40274-013-0603-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0603-3